Medibank share price edges lower amid $31 million joint venture news

The Medibank joint venture with Aurora Healthcare aims to integrate inpatient and out-of-hospital care.

Key points
  • The Medibank share price has dipped into the red
  • The ASX 200 health insurer has entered into a 50/50 joint venture with Aurora Healthcare, known as iMH
  • iMH will initially invest $31 million to establish three mental-health hospitals

The Medibank Private Ltd (ASX: MPL) share price has dipped into the red in early morning trade, down 0.3%.

Shares in the S&P/ASX 200 Index (ASX: XJO) financial services stock, Australia's biggest health insurer, closed yesterday trading for $3.26. Shares are currently swapping hands for $3.25.

This comes after more than $5.3 million worth of shares have already changed hands this morning following news of a $31 million joint venture.

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.

Image source: Getty Images

What's happening with the joint venture?

The Medibank share price is edging lower amid news that the company has entered into a 50/50 joint venture with Aurora Healthcare, known as iMH, that will establish three mental-health hospitals.

iMH will initially invest $31 million into the three hospitals delivering 153 new mental health beds along with out-of-hospital support services like telehealth in home and community settings.

Aurora Healthcare is providing two hospitals in New South Wales and the Australian Capital Territory, Deakin Private Hospital and Hirondelle Private hospital. iMH will invest in a new 56-bed mental health facility. That will be developed in Alexandria, New South Wales.

The joint venture's acquisition of Deakin Private Hospital and Hirondelle Private hospital has been completed. The investment for the new facility in Alexandria is in the pipeline.

Executive commentary

Commenting on the development, Aurora Healthcare Australia CEO Julia Strickland-Bellamy, said:

The model will address the clear unmet demand in the community. In our network alone, the wait list for outpatient psychiatry has been at around six months over the past two years.

Providing people with treatment options beyond what has historically been solely hospital-centric care will help to support greater access, choice and flexibility.

Addressing the issue that the health insurer might influence a patient's decisions, Strickland-Bellamy said, "It's ultimately about the most appropriate treatment pathway for each individual patient, regardless of their private health insurer. All decisions about their suitability for the model will be made by the patient alongside their doctor and the hospital's clinical team."

Medibank group executive and CEO of Amplar Health Andrew Wilson said, "Integrating inpatient and out-of-hospital care helps patients access support when and where they need it."

Wilson added:

It shouldn't have to be one or the other. Many patients would benefit from the iMH model, which is designed around their individual needs and circumstances under the direction of their treating psychiatrist.

Deakin Private Hospital will open in the coming months, while Hirondelle Private Hospital is expected to open later this year.

Medibank share price snapshot

As you can see in the chart below, the Medibank share price has had a good run in 2023, up 10% since the closing bell on 30 December.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech could rise almost 50%, Morgans says

Turning science into contracts could unlock value for this company.

Read more »